Trial Profile

A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the Treatment of Moderate to Severe Acne Vulgaris in Adults With Photodynamic Therapy (PDT)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2026 According to Biofrontera media release, results are expected to be presented to the FDA in early Q3 2026 and are intended to provide the basis of a future Phase 3 program
09 Jan 2026 According to Biofrontera media release, company announced the successful database lock of the study on January 5, 2026. All data from participants that is collected throughout study is captured in a specific database. Data for to be available in February of this year.
22 Dec 2025 Planned End Date changed from 1 Nov 2025 to 1 Jan 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com